FAM169BP
Protein FAM169BP
Also known as: F169B_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for FAM169BP in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
192 residues, UniProt reviewed canonical sequence.
>Q8N8A8|FAM169BP
1 MKVQSFGERV VLFILNAIIF GRLERNLDDD DMFFLPHSVK EQAKILWRRG AAVGFYTTKM
61 KGRLCGDGTG ACYLLPVFDT VFIRRKHWHR GLGTAMLRDF CETFPEDEAL GVSCSMSPAM
121 YQAHPGNSED VSRHARTSQN DRPRQPAPGD GSKERMCGEE LEDTKDDPEC GVEEEDAGLA
181 GQPPGKLTRS SPLocalizationUniProt · AlphaFold · HPA
Whether an antibody against FAM169BP can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.5
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
Protein domainsUniProt · Pfam · InterPro
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads FAM169BP as an antibody target. Whether an autoantibody or antibody against FAM169BP could matter depends on whether native FAM169BP is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
FAM169BP is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label FAM169BP as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...